Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novasep Invests In Drug Conjugates

by Rick Mullin
July 6, 2015 | A version of this story appeared in Volume 93, Issue 27

The contract manufacturing organization (CMO) Novasep plans to build an antibody-drug conjugate (ADC) facility at its site in Le Mans, France. The $11 million project will enhance the company’s current ADC offering with what it calls full bioconjugation services. “Novasep is one of the few CMOs able to produce both commercial-scale ADC payloads and monoclonal antibodies,” says Thierry van Nieuwenhove, president of Novasep’s synthesis business unit. The company expects the facility to open by mid-2016.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.